Eddy Yang is an Oncology physician affiliated with University of Kentucky. OpenAlex indexes 556 publications with 7,916 citations (h-index 47); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
800 Rose St
Lexington, KY 405361801
Telephone
859-257-7618Provider last certified this registry record 27 Jan 2023.
Clinical trials
- Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer
Sponsor: University of Alabama at Birmingham
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Siemens Medical Solutions USA, Inc.Program year20254 payments
- Elekta, Inc.Program year20251 payment
- GE HEALTHCAREProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
61.3%Opioid Agonist61.3%Oxycodone Hcl100%Part D<11 patientsGenitourinary & hormones
38.7%alpha-Adrenergic Blocker38.7%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Journal of Clinical Oncology
2020 - Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy
Nature Communications
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Ain, MD
University of Kentucky
Zhonglin Hao, MD, PhD
University of Kentucky
David Mannino, MD
University of Kentucky
David Moliterno, MD
University of Kentucky
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”